company background image
ARGX logo

argenx ENXTBR:ARGX Stock Report

Last Price

€337.30

Market Cap

€20.0b

7D

-4.3%

1Y

-4.4%

Updated

19 Apr, 2024

Data

Company Financials +

ARGX Stock Overview

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.

ARGX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

argenx SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for argenx
Historical stock prices
Current Share Price€337.30
52 Week High€494.10
52 Week Low€271.00
Beta0.36
1 Month Change3.37%
3 Month Change1.87%
1 Year Change-4.45%
3 Year Change38.64%
5 Year Change205.80%
Change since IPO4,169.62%

Recent News & Updates

Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

Apr 11
Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24
Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Recent updates

Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

Apr 11
Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24
Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Mar 05
Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

Feb 23
argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Dec 18
Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

Jul 28
Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Jul 17
An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Revenues Tell The Story For argenx SE (EBR:ARGX)

Jun 20
Revenues Tell The Story For argenx SE (EBR:ARGX)

argenx (EBR:ARGX) Is Using Debt Safely

May 08
argenx (EBR:ARGX) Is Using Debt Safely

We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

Apr 20
We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?

Dec 27
Does argenx (EBR:ARGX) Have A Healthy Balance Sheet?

We're Not Very Worried About argenx's (EBR:ARGX) Cash Burn Rate

Oct 08
We're Not Very Worried About argenx's (EBR:ARGX) Cash Burn Rate

Growth Investors: Industry Analysts Just Upgraded Their argenx SE (EBR:ARGX) Revenue Forecasts By 71%

Jul 29
Growth Investors: Industry Analysts Just Upgraded Their argenx SE (EBR:ARGX) Revenue Forecasts By 71%

Shareholder Returns

ARGXBE BiotechsBE Market
7D-4.3%-2.6%-0.7%
1Y-4.4%-12.3%-5.4%

Return vs Industry: ARGX exceeded the Belgian Biotechs industry which returned -12.3% over the past year.

Return vs Market: ARGX matched the Belgian Market which returned -5.4% over the past year.

Price Volatility

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement5.7%
Biotechs Industry Average Movement7.6%
Market Average Movement3.7%
10% most volatile stocks in BE Market7.9%
10% least volatile stocks in BE Market2.5%

Stable Share Price: ARGX has not had significant price volatility in the past 3 months.

Volatility Over Time: ARGX's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
20081,148Tim Van Hauwermeirenwww.argenx.com

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
ARGX fundamental statistics
Market cap€20.03b
Earnings (TTM)-€276.97m
Revenue (TTM)€1.19b

16.8x

P/S Ratio

-72.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARGX income statement (TTM)
RevenueUS$1.27b
Cost of RevenueUS$977.33m
Gross ProfitUS$291.27m
Other ExpensesUS$586.32m
Earnings-US$295.05m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 09, 2024

Earnings per share (EPS)-4.97
Gross Margin22.96%
Net Profit Margin-23.26%
Debt/Equity Ratio0%

How did ARGX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.